This ASX 200 healthcare share is diving 13% as short sellers take aim

A short seller is describing this company's Daybue product as a 'flop'.

| More on:
Shot of a senior scientist looking stressed out while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are ending the week deep in the red.

The ASX 200 healthcare share was down 13% to $20.04 before being paused from trade.

What's going on with this ASX 200 healthcare share?

Investors have been heading to the exits today after a short seller targeted its US partner Acadia Pharmaceuticals Inc (NASDAQ: ACAD).

According to a note out of Culper Research, it is shorting Acadia due to concerns over the Daybue product which is licenced to it from Neuren Pharmaceuticals.

Culper Research believes that key stakeholders have turned "sour" on Daybue, which could be bad news for the ASX 200 healthcare share.

It has been generating significant revenue from royalties and milestone payments over the last 12 months amid strong demand for the only approved treatment for Rett Syndrome.

But this revenue generation may not last, with the short seller describing Daybue as a "flop". It said:

We believe ACADIA's April 2023 launch of Daybue – the Company's highly-anticipated "first and only" drug to treat Ret Syndrome – has been a total flop.

Despite an initial outburst of interest in the drug, our research reveals that patients, caregivers, physicians, and insurers have all soured on the drug.

The sell-side sell calls for over $800 million in peak Daybue revenues, but our research suggests that Daybue new patient starts already topped this past summer, peak revenues will be a mere fraction of sell-side estimates, and Daybue's flop will have knock-on effects as ACADIA remains a cash-burning machine.

Insiders see the writing on the wall: ACADIA's Head of R&D, its Chief Science Officer, and its General Counsel have all left in the past 3 months. We think shares are headed much lower.

'Horror stories'

Culper Research also alleges that Acadia has misrepresented Daybue's safety profile and that there are "horror stories" being reported by users. It adds:

We think ACADIA has misrepresented Daybue's safety profile, and in turn, patient retention rates. The Company has constantly characterized Daybue's side effects as mild and manageable, but our analysis of FAERS data suggests that roughly 1 of every 10 to 11 Daybue patients end up hospitalized.

These horror stories have now made their way through the Ret community. Multiple high-prescribing physicians collectively told us that collectively, close to half of their patients are now no longer even interested in trying Daybue.

Neuren hasn't revealed why its shares are paused from trade. But it's quite likely the ASX 200 healthcare share is preparing a response to these allegations.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Private health insurance diagram.
Healthcare Shares

What's Macquarie's price target for NIB shares?

Is the broker positive or negative on NIB's shares?

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 42% on Pro Medicus investment

Let's see what is going on today with this small cap.

Read more »

Six smiling health workers pose for a selfie.
Earnings Results

ResMed share price hits record high on strong FY25 results

This healthcare giant is ending the week positively thanks to its strong results.

Read more »

Two doctors smile as they sit together at a desk looking at a patient's x-ray.
Healthcare Shares

Why Macquarie rates this ASX All Ords medical imaging stock a buy

The broker maintains its outperform rating on the stock.

Read more »

A man in a hospital bed on a drip gives a thumbs up sign.
Healthcare Shares

Macquarie predicts 86% upside for this ASX 200 healthcare stock

Shares could almost double over the next 12 months, according to the broker.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »